[
  {
    "ts": null,
    "headline": "Earnings Preview: Gilead Sciences (GILD) Q4 Earnings Expected to Decline",
    "summary": "Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=afe52c8c8e1fa8800a0da60c8c4f1253585eb6cb7d700e9c5960a9d4396584aa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770130812,
      "headline": "Earnings Preview: Gilead Sciences (GILD) Q4 Earnings Expected to Decline",
      "id": 138344196,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=afe52c8c8e1fa8800a0da60c8c4f1253585eb6cb7d700e9c5960a9d4396584aa"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why Gilead Sciences Stock Surged 21% in a Month",
    "summary": "GILD shares gain traction post Jan. 20 after NEJM data show Trodelvy plus Keytruda cut progression risk 35% in first-line PD-L1+ metastatic TNBC, signaling a new care standard.",
    "url": "https://finnhub.io/api/news?id=cc1116d179a24e39c202e25a799f76a3cca78d58bde0b18f97992ac65af7ce55",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770128820,
      "headline": "Here's Why Gilead Sciences Stock Surged 21% in a Month",
      "id": 138344143,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "GILD shares gain traction post Jan. 20 after NEJM data show Trodelvy plus Keytruda cut progression risk 35% in first-line PD-L1+ metastatic TNBC, signaling a new care standard.",
      "url": "https://finnhub.io/api/news?id=cc1116d179a24e39c202e25a799f76a3cca78d58bde0b18f97992ac65af7ce55"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Oncology Push Gains Traction With Trodelvy Keytruda Results",
    "summary": "Gilead Sciences reported positive Phase 3 results for Trodelvy combined with Keytruda in first-line PD-L1+ metastatic triple-negative breast cancer. The data, published in The New England Journal of Medicine, point to meaningful clinical benefits in this hard-to-treat setting. Gilead also entered a licensing agreement with Repare Therapeutics to expand its DNA-repair-targeted oncology pipeline. These developments highlight Gilead's increased focus on oncology alongside its established...",
    "url": "https://finnhub.io/api/news?id=820b43a035fd6dcf03953506bd1ecc457d98828ef2eac71776fbc4d824f0784e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770099052,
      "headline": "Gilead Sciences Oncology Push Gains Traction With Trodelvy Keytruda Results",
      "id": 138339523,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences reported positive Phase 3 results for Trodelvy combined with Keytruda in first-line PD-L1+ metastatic triple-negative breast cancer. The data, published in The New England Journal of Medicine, point to meaningful clinical benefits in this hard-to-treat setting. Gilead also entered a licensing agreement with Repare Therapeutics to expand its DNA-repair-targeted oncology pipeline. These developments highlight Gilead's increased focus on oncology alongside its established...",
      "url": "https://finnhub.io/api/news?id=820b43a035fd6dcf03953506bd1ecc457d98828ef2eac71776fbc4d824f0784e"
    }
  },
  {
    "ts": null,
    "headline": "1 Safe-and-Steady Stock with Competitive Advantages and 2 Facing Challenges",
    "summary": "A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.",
    "url": "https://finnhub.io/api/news?id=f72aebffa160a0543f3de1b8515a3712b612452d5799db84f9f505cf150e9272",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770093417,
      "headline": "1 Safe-and-Steady Stock with Competitive Advantages and 2 Facing Challenges",
      "id": 138340070,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.",
      "url": "https://finnhub.io/api/news?id=f72aebffa160a0543f3de1b8515a3712b612452d5799db84f9f505cf150e9272"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences, Inc. (GILD): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Gilead Sciences, Inc. on Disruptive analytics’s Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on GILD. Gilead Sciences, Inc.’s share was trading at $141.95 as of January 30th. GILD’s trailing and forward P/E were 21.60 and 15.87 respectively according to Yahoo Finance. Gilead Sciences (GILD), historically […]",
    "url": "https://finnhub.io/api/news?id=059eac3b071f27e6a122b43493500742bba36cf554bab207b4f771d29acbda3b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770078569,
      "headline": "Gilead Sciences, Inc. (GILD): A Bull Case Theory",
      "id": 138338014,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Gilead Sciences, Inc. on Disruptive analytics’s Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on GILD. Gilead Sciences, Inc.’s share was trading at $141.95 as of January 30th. GILD’s trailing and forward P/E were 21.60 and 15.87 respectively according to Yahoo Finance. Gilead Sciences (GILD), historically […]",
      "url": "https://finnhub.io/api/news?id=059eac3b071f27e6a122b43493500742bba36cf554bab207b4f771d29acbda3b"
    }
  }
]